$Phathom Pharmaceuticals (PHAT.US)$ In a report released today,  from Needham maintained a Buy rating on Phathom Pharmaceuticals ( – ), with a price target of $26.00.
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...

$Phathom Pharmaceuticals (PHAT.US)$ FDA Approves VOQUEZNA® for Relief of Heartburn
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏

$Soligenix (SNGX.US)$ shares skyrocketed more than 400% in recent Tuesday trading after the company reported positive results of a study evaluating extended HyBryte treatment in patients with early-stage cutaneous T-cell lymphoma.
The company said six patients were enrolled in the Phase 3 FLASH study and treated with HyBryte over a period of up to 44 weeks, and they responded positively to the therapy with 75% achieving "treatment success."

$Anew Medical (WENA.US)$
ANEW Medical Shares Are Trading Higher After the Company Announced That Is Has Been Granted and Issued a Patent in Europe, EP3377091B1, for the Use of Its Klotho Gene Sequence and Gene Delivery Systems for the Treatment of Diminished Cognition, Memory Loss, Dementia and Other Neurodegenerative Diseases

$Tesla (TSLA.US)$ is set to hold its annual shareholder meeting on June 13, with investors voting on whether to reapprove CEO Elon Musk's $55.8 billion pay package. The AGM outcome could affect Tesla's future trajectory and reveal shareholder sentiments on crucial governance matters. How will TSLA's annual meeting results drive its share price?  Make your guess now!
Rewards
● An equal share of 10,000 points: For mooers ...